1. Market Research
  2. > Pharmaceutical Market Trends
Global Drug Discovery and Early Development Outsourcing Growth Opportunities

Global Drug Discovery and Early Development Outsourcing Growth Opportunities

  • August 2021
  • 58 pages
  • ID: 6130908
  • Format: PDF
  • Frost & Sullivan

Summary

Table of Contents

The analyst presents post-COVID-19 growth opportunities and strategic imperatives for the global drug discovery and early development outsourcing market in this study, which covers research and development (R&D) efforts, market trends, key participants, drivers and restraints of market adoption, and recent mergers and acquisitions. The report identifies the evolving competitive landscape and initiatives taken by key contract research organizations (CRO) and contract development and manufacturing organizations (CDMO) to adapt to the growing needs of pharmaceutical and biotechnology sponsors. The drug discovery and early development outsourcing market was worth $19.65 billion in 2020 and is estimated to grow at a compound annual growth rate of 6.4% up to 2026, with North America continuing to lead the market. In terms of overall R&D expenditure, the contribution of large pharmaceutical companies is steadily declining due to their focus on leaner portfolios. In contrast, the contribution of emerging biotechnology companies to drug development has grown more than 80% since 2018. Pharmaceutical companies are directing their R&D spending mainly toward strengthening their oncology portfolio and increasing year-on-year acquisitions of clinical-stage biopharmaceutical companies focusing on oncology therapy, suggesting both the potential of new technologies and promising returns on investment for these assets. Leading CROs and CDMOs are also focused on oncology, with anticancer drugs reportedly contributing the highest to the drug development pipeline in 2020. COVID-19-related drug discovery and early development research is projected to slow down in 2022 as most projects would have advanced to the clinical research stage by then. When pandemic-related restrictions are lifted, a surge in outsourcing for the next two years is expected as companies resume their non-COVID-19 drug discovery programs that were stalled during the pandemic.In the United States and Europe, testing service providers with best-in-class good laboratory practices (GLP) and good track records are the preferred partner for completing investigational new drugs–enabling studies. Global CROs may have in-house capabilities, but pharmaceutical companies still prefer independent validation from specialists to minimize the risk of failure early on in the development life cycle before moving toward regulatory filing. Key industry participants are positioning themselves to be end-to-end integrated service providers for pharmaceutical and biotechnology sponsors. The growing demand for end-to-end integrated drug discovery and development support is closing the gap that distinguishes a CRO from a CDMO. The promise of artificial intelligence in drug discovery, along with novel approaches to target “undruggable” RNA, is set to drive small molecule drug discovery and outsourcing while the growth in biologics is expected to boost the need for better disease models and advanced in vivo pharmacology capabilities. Exploring novel expression systems to support the urgent needs of infectious disease management is also forecast to gain momentum especially as the industry favors single-use reactors for future biotherapeutics.
Author: Meghna Hiren Thakkar

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Toxicology Services Global Market - Forecast To 2028

  • $ 4950
  • November 2021
  • 411 pages

Toxicology is the study of adverse effects that occur in living organisms and its environment due to chemicals, physical or biological substances at ambient exposure levels. Toxicology testing regulations ...

  • World
  • United States
  • Pharmaceutical
  • Medical Device
  • Industry analysis
  • Drug Approval

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on